Roche Holding Valuation
Is ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ROG (CHF274) is trading below our estimate of fair value (CHF692.2)
Significantly Below Fair Value: ROG is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ROG?
Other financial metrics that can be useful for relative valuation.
What is ROG's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 221.22b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | 11.7x |
PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does ROG's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 41x | ||
NOVN Novartis | 25.1x | 10.2% | CHF 202.1b |
DESN Dottikon ES Holding | 43.8x | n/a | CHF 3.5b |
LONN Lonza Group | 56.2x | 20.6% | CHF 36.8b |
AZN AstraZeneca | 39x | 15.7% | UK£189.8b |
ROG Roche Holding | 19x | 8.3% | CHF 221.2b |
Price-To-Earnings vs Peers: ROG is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (41x).
Price to Earnings Ratio vs Industry
How does ROG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ROG is good value based on its Price-To-Earnings Ratio (19x) compared to the European Pharmaceuticals industry average (25.9x).
Price to Earnings Ratio vs Fair Ratio
What is ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19x |
Fair PE Ratio | 36.6x |
Price-To-Earnings vs Fair Ratio: ROG is good value based on its Price-To-Earnings Ratio (19x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 274.00 | CHF 274.00 0% | 19.8% | CHF 432.00 | CHF 210.00 | n/a | 19 |
Jul ’25 | CHF 250.10 | CHF 278.58 +11.4% | 20.4% | CHF 428.00 | CHF 210.00 | n/a | 19 |
Jun ’25 | CHF 231.00 | CHF 277.53 +20.1% | 20.5% | CHF 428.00 | CHF 210.00 | n/a | 19 |
May ’25 | CHF 220.60 | CHF 279.83 +26.9% | 20.6% | CHF 428.00 | CHF 210.00 | n/a | 18 |
Apr ’25 | CHF 229.70 | CHF 281.28 +22.5% | 19.9% | CHF 424.00 | CHF 210.00 | n/a | 18 |
Mar ’25 | CHF 233.20 | CHF 282.94 +21.3% | 19.3% | CHF 424.00 | CHF 210.00 | n/a | 18 |
Feb ’25 | CHF 233.50 | CHF 298.00 +27.6% | 19.5% | CHF 450.00 | CHF 225.00 | n/a | 18 |
Jan ’25 | CHF 244.50 | CHF 307.11 +25.6% | 19.6% | CHF 472.00 | CHF 225.00 | n/a | 19 |
Dec ’24 | CHF 239.60 | CHF 307.83 +28.5% | 18.7% | CHF 472.00 | CHF 225.00 | n/a | 18 |
Nov ’24 | CHF 237.70 | CHF 307.83 +29.5% | 18.7% | CHF 472.00 | CHF 225.00 | n/a | 18 |
Oct ’24 | CHF 250.45 | CHF 313.44 +25.2% | 17.2% | CHF 478.00 | CHF 250.00 | n/a | 18 |
Sep ’24 | CHF 259.45 | CHF 321.12 +23.8% | 16.6% | CHF 477.27 | CHF 250.00 | n/a | 19 |
Aug ’24 | CHF 270.60 | CHF 326.77 +20.8% | 16.1% | CHF 477.48 | CHF 250.00 | n/a | 20 |
Jul ’24 | CHF 273.50 | CHF 328.02 +19.9% | 16.0% | CHF 456.47 | CHF 250.00 | CHF 250.10 | 19 |
Jun ’24 | CHF 289.75 | CHF 333.63 +15.1% | 15.9% | CHF 456.47 | CHF 250.00 | CHF 231.00 | 21 |
May ’24 | CHF 280.35 | CHF 335.49 +19.7% | 15.3% | CHF 450.00 | CHF 250.00 | CHF 220.60 | 22 |
Apr ’24 | CHF 260.95 | CHF 344.08 +31.9% | 15.3% | CHF 450.00 | CHF 250.00 | CHF 229.70 | 23 |
Mar ’24 | CHF 271.10 | CHF 349.87 +29.1% | 13.9% | CHF 450.00 | CHF 250.00 | CHF 233.20 | 24 |
Feb ’24 | CHF 279.40 | CHF 354.91 +27.0% | 13.3% | CHF 465.00 | CHF 265.00 | CHF 233.50 | 24 |
Jan ’24 | CHF 290.50 | CHF 371.08 +27.7% | 11.0% | CHF 450.00 | CHF 300.00 | CHF 244.50 | 24 |
Dec ’23 | CHF 310.00 | CHF 373.83 +20.6% | 10.6% | CHF 450.00 | CHF 300.00 | CHF 239.60 | 24 |
Nov ’23 | CHF 329.50 | CHF 375.29 +13.9% | 10.5% | CHF 450.00 | CHF 300.00 | CHF 237.70 | 24 |
Oct ’23 | CHF 323.45 | CHF 376.25 +16.3% | 10.8% | CHF 450.00 | CHF 300.00 | CHF 250.45 | 24 |
Sep ’23 | CHF 312.80 | CHF 374.13 +19.6% | 9.5% | CHF 444.00 | CHF 300.00 | CHF 259.45 | 23 |
Aug ’23 | CHF 315.40 | CHF 374.13 +18.6% | 9.5% | CHF 444.00 | CHF 300.00 | CHF 270.60 | 23 |
Jul ’23 | CHF 320.40 | CHF 386.26 +20.6% | 10.0% | CHF 475.80 | CHF 330.00 | CHF 273.50 | 23 |
Analyst Forecast: Target price is less than 20% higher than the current share price.